TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04502212

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hepatic Ultrasound Insonification
Description: Hepatic ultrasound insonification will be performed after an overnight fast (no food or drinks except for water for at least 10 hours) at approximately the same time on each day for three days.
Study: NCT03362606

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OC-CTLs
Description: 2 to 4 infusions, once a week, for 1x10\^5\~4x10\^6 CTLs/kg via IV, abdominal cavity or tumor injection each time
Study: NCT00553735

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine A 0.05%
Description: Topical cyclosporine A 0.05% (Restasis) three times a day for 18 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Arificial Tear
Description: Artificial Tear - three times a day for 18 months.
Study: NCT03904108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: platinum doublets chemotherapy plus ramucirumab, intravenously(IV)
Study: NCT00561418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Vorinostat (SAHA) will be administered orally starting approximately day +60 post HSCT for 21 consecutive days of a 28-day cycle for up to a maximum of 11 cycles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Correlative studies
Description: Laboratory as well as quality of life correlative studies will be obtained at days +26 to +38 (at approximately 1 month post HSCT),days +56 to +66 (≈2 mos), and at Cycle 2 Day 1 (≈3 mos.), Cycle 3 Day 1 (≈4 mos.), Cycle 5 Day 1 (≈6 mos.),Cycle 7 Day 1 (≈8 mos.), and off study (ideally at ≈12 mos.)
Study: NCT03731442

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Involved field irradiation
Description: Involved field irradiation; intensity-modulated radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Elective field irradiation
Description: Elective field irradiation; intensity-modulated radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 135-150mg/m2, d1, every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 135-150mg/m2, d1, every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum
Description: for lobaplatin, 30mg/m2, d1-2, total dose should not exceed 50mg,every 3 weeks; for nedaplatin 50mg/m2, d1-2, every 3 weeks;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum
Description: for lobaplatin, 30mg/m2, d1-2, total dose should not exceed 50mg,every 3 weeks; for nedaplatin 50mg/m2, d1-2, every 3 weeks;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhG-CSF
Description: PEG-rhG-CSF 3-6mg, 48 hours after chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhG-CSF
Description: PEG-rhG-CSF 3-6mg, 48 hours after chemotherapy
Study: NCT03987074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Solution administered subcutaneously with pre-filled PDS290 pen-injector once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Firsocostat
Description: Tablets administered orally once daily
Study: NCT01322230

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Multimedia Control

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WISEMD Original
Description: Current WISEMD

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Social Networking
Description: Social networking feature

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Social Networking plus Emotional Design
Description: social networking features plus user interface enhancements
Study: NCT02842138

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous anti-CD19 CAR T cells
Description: Patients will receive a three-day regimen of chemotherapy consisting of fludarabine and cyclophosphamide aimed to deplete the lymphocytes. Four days after lymphodepletion, patients are intravenously infused autologous anti-CD19 CAR T cells. A prescribed CAR T cell dose will be intravenously infused to patient in a three-day split-dose regimen (day0,30%; day1, 30%; day2, 40%).
Study: NCT03997851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Topical acetaminophen gel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Topical acetaminophen gel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Topical acetaminophen gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carbomer 980
Description: Topical vehicle gel
Study: NCT02644473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Control
Study: NCT00281957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tipifarnib
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: Given IV
Study: NCT02404766

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: C0-C1 dorsal glide manual mobilization

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: C7-T1 ventral cranial glide manual mobilization
Study: NCT03108378

Intervention type: PROCEDURE
Intervention: Surgery
Description: hip, shoulder or knee replacement surgery, limb amputations or other orthopedic surgical procedures

Intervention type: PROCEDURE
Intervention: Surgery
Description: hip, shoulder or knee replacement surgery, limb amputations or other orthopedic surgical procedures

Intervention type: PROCEDURE
Intervention: Surgery
Description: hip, shoulder or knee replacement surgery, limb amputations or other orthopedic surgical procedures

Intervention type: PROCEDURE
Intervention: Surgery
Description: hip, shoulder or knee replacement surgery, limb amputations or other orthopedic surgical procedures

Intervention type: PROCEDURE
Intervention: Surgery
Description: hip, shoulder or knee replacement surgery, limb amputations or other orthopedic surgical procedures
Study: NCT04646876

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate
Description: Prospective , comparative , double blind study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Prospective , comparative , double blind study
Study: NCT01273896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STA-9090
Description: All patients will receive 200 mg/m2 of STA-9090 once weekly by a 1-hour IV infusion for three consecutive weeks followed by a 1 week dose-free interval. Subjects tolerating therapy may continue on study until disease progression.
Study: NCT02005835

Intervention type: OTHER
Group type: OTHER
Intervention: Community based peer support
Description: Community-based Support from Peer Mothers (Expert mothers):~Routine standard clinical care based on the MoH guidelines Mentor mothers provide education and psychosocial support in community prior to each visit Monthly support groups in community Home visits for each missed appointment

Intervention type: OTHER
Group type: OTHER
Intervention: Facility-based Peer Support
Description: Facility-based Peer Support to provide the following at the clinic~Routine standard clinical care based on the MoH guidelines Mentor mothers provide education and psychosocial support at facility Weekly support groups provided in clinic Phone call, SMS, or home visit for each missed appointment
Study: NCT03946618

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Summit System, Olympus
Description: Electrical brain stimulation with an implantable pulse generator
Study: NCT04346979

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation-Based
Description: 25 volunteers postmenopausal women who are at home during the social isolation process due to the coronavirus outbreak will be included in this group. Online yoga and mindfulness protocol was created for individuals who will participate in the study. Each training protocol was planned as 30 minutes for 3 days a week for 6 weeks. It was planned to start the protocol with warm-up exercises and finish with cooling exercises. Respiratory exercise was added to the training protocol. Individuals were asked to participate in the study via telerehabilitation system and aimed to do their exercises with a physiotherapist.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video-Based
Description: 25 volunteers postmenopausal women who are at home during the social isolation process due to the coronavirus outbreak will be included in this group. Online yoga and mindfulness protocol was created for individuals who will participate in the study. Each training protocol was planned as 30 minutes for 3 days a week for 6 weeks. It was planned to start the protocol with warm-up exercises and finish with cooling exercises. The respiratory exercise was added to the training protocol. Video recordings containing only yoga and mindfulness training were sent to individuals. The participants were supervised by the researcher.
Study: NCT00623545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Exenatide dose was 5 microgram for 2 weeks that was increased to 10 microgram for 10 weeks of treatment.
Study: NCT03630744

Intervention type: OTHER
Intervention: Fluid therapy
Description: * Analyze the type of fluid administered:~  * crystalloids:~    * Saline serum 0.9% ....... ml~   * Ringer Lactate ........ ml~   * Isofundin ® ........ ml~   * Plasmalyte® ... ... ml~   * Glucose Serum 5% ....... ml~   * Glucose serum 10% ........ ml~ * Glucosaline serum ........ ml~ * colloids:~    * Hydroxyethyl starch 130 / 0.4 ... ... ml~   * Hydroxyethyl alimdon 130 / 0.42 ... .... ml~   * Gelatins ... ....... ml~   * Albumin 5% .......... ml~ * Albumin 20% .......... ml.~* Analyze the total amount of crystalloids and liquid colloids administered in 24 hours in milliliters.~* Analyze the form of administration:~  * Standard~ * Standard with dosimeters~ * on pump
Study: NCT04337736

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical exercise
Study: NCT03234348

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Description: PCI + stent implantation

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Percutaneous coronary intervention
Description: PCI + stent implantation
Study: NCT04545437

Intervention type: OTHER
Intervention: Admission to ICU
Description: Exposure is admission to an Intensive Care Unit
Study: NCT02311569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: 25 mg daily during the first week followed by 50 mg Mirabegron daily during the remaining treatment period.
Study: NCT03741803

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Delayed cord clamping
Description: The umbilical cord will be clamped after 60 seconds after birth

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Early cord clamping
Description: The umbilical cord will be clamped as soon as feasible after birth, usually within the initial 15 seconds after birth.
Study: NCT00499655

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: erlotinib hydrochloride
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: Given orally

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Given orally

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: immunohistochemistry staining method
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: fluorescence in situ hybridization
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: fluorescence in situ hybridization
Description: Correlative studies

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: mutation analysis
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: mutation analysis
Description: Correlative studies

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: protein expression analysis
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: protein expression analysis
Description: Correlative studies

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: gene expression analysis
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: Correlative studies
Study: NCT03987074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Firsocostat
Description: Tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilofexor
Description: Tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilofexor
Description: Tablets administered orally once daily
Study: NCT04345263

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MTA pulpotomy
Description: Cutting the coronal portion of the pulp to the level of canal orifices and applying the dressing and restoration
Study: NCT03506607

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise in hypoxia 1500m
Description: Subjects will perform a 6-min treadmill exercise wearing an oronasal mask connected (through a hose) with a three-way valve to an altitude simulation device (Altitrainer; SMTech, Nyon, Switzerland). The ambient air will be mixed with nitrogen and inspired oxygen fraction will be reduced to 16%. The first 3 min will be performed at 70% of the mean speed calculated during a previous visit, and the last 3 min at an intensity between 12-14 on the Borg's scale.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise in hypoxia 2500m
Description: Subjects will perform a 6-min treadmill exercise wearing an oronasal mask connected (through a hose) with a three-way valve to an altitude simulation device (Altitrainer; SMTech, Nyon, Switzerland). The ambient air will be mixed with nitrogen and inspired oxygen fraction will be reduced to 14%. The first 3 min will be performed at 70% of the mean speed calculated during a previous visit, and the last 3 min at an intensity between 12-14 on the Borg's scale.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercise in normoxia
Description: Subjects will perform a 6-min treadmill exercise wearing an oronasal mask connected (through a hose) with a three-way valve to an altitude simulation device (Altitrainer; SMTech, Nyon, Switzerland). For the exercise performed in normoxia conditions, subjects will breathe room air. The first 3 min will be performed at 70% of the mean speed calculated during a previous visit, and the last 3 min at an intensity between 12-14 on the Borg's scale.
Study: NCT00602576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Given orally
Study: NCT02057198

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fidaxomicin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Study: NCT02935322

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.12 % chlorhexidine + 0.2 % NaF mouthrinse
Description: In study I, subjects were asked to refrain from tooth brushing and interdental cleaning and rinse with 10 ml of the assigned test solution for one minute, twice daily (morning and evening) during 4 days.~In study II, subjects were asked to rinse with 10ml of the assigned test solution twice daily after tooth brushing during a 6-week period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.2 % NaF mouthrinse
Description: In study I, subjects were asked to refrain from tooth brushing and interdental cleaning and rinse with 10 ml of the assigned test solution for one minute, twice daily (morning and evening) during 4 days.~In study II, subjects were asked to rinse with 10ml of the assigned test solution twice daily after tooth brushing during a 6-week period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.12% chlorhexidine
Description: In study I, subjects were asked to refrain from tooth brushing and interdental cleaning and rinse with 10 ml of the assigned test solution for one minute, twice daily (morning and evening) during 4 days.~In study II, subjects were asked to rinse with 10ml of the assigned test solution twice daily after tooth brushing during a 6-week period.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Contained all basic ingredients as the other three mouthrinses but no chlorhexidine and no NaF. In study I, subjects were asked to refrain from tooth brushing and interdental cleaning and rinse with 10 ml of the assigned test solution for one minute, twice daily (morning and evening) during 4 days.~In study II, subjects were asked to rinse with 10ml of the assigned solution twice daily after tooth brushing during a 6-week period.
Study: NCT03351179

Intervention type: COMBINATION_PRODUCT
Intervention: clinical characteristics, previous history, laboratory bio-markers, echocardiographic measurements, angiographic findings,clinical outcomes
Description: The differences of data(clinical characteristics, history, laboratory biomarkers, echocardiographic measurements, angiographic characteristics and clinical outcomes) in two groups were conducted. The differences between two groups were compared (clinical characteristics, history, laboratory biomarkers, echocardiographic measurements, angiographic characteristics and clinical outcomes) in two groups were compared, and then found the risk factors. Following,the incidence of clinical outcomes and mortality were compared. Then, univariate logistic regression and multivariate logistic regression analysis adjusted for significant risk factors were performed to find out the independent predictive factors. Finally, the ROC was constructed, and the area was evaluated to assess the predicted probability of regression model.

Intervention type: COMBINATION_PRODUCT
Intervention: clinical characteristics, previous history, laboratory bio-markers, echocardiographic measurements, angiographic findings,clinical outcomes
Description: The differences of data(clinical characteristics, history, laboratory biomarkers, echocardiographic measurements, angiographic characteristics and clinical outcomes) in two groups were conducted. The differences between two groups were compared (clinical characteristics, history, laboratory biomarkers, echocardiographic measurements, angiographic characteristics and clinical outcomes) in two groups were compared, and then found the risk factors. Following,the incidence of clinical outcomes and mortality were compared. Then, univariate logistic regression and multivariate logistic regression analysis adjusted for significant risk factors were performed to find out the independent predictive factors. Finally, the ROC was constructed, and the area was evaluated to assess the predicted probability of regression model.
Study: NCT01813539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARGX-110
Description: ARGX-110 will be administered as an IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARGX-110
Description: ARGX-110 will be administered as an IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARGX-110
Description: ARGX-110 will be administered as an IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARGX-110
Description: ARGX-110 will be administered as an IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARGX-110
Description: ARGX-110 will be administered as an IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARGX-110
Description: ARGX-110 will be administered as an IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARGX-110
Description: ARGX-110 will be administered as an IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARGX-110
Description: ARGX-110 will be administered as an IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARGX-110
Description: ARGX-110 will be administered as an IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARGX-110
Description: ARGX-110 will be administered as an IV infusion.
Study: NCT02969824

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised Aerobic Exercise
Description: The AE protocol will consist of eight sessions that proceed in a stepwise fashion in terms of duration and intensity over 11 days. Exercise will be performed on the Velotron Pro stationary cycle ergometer (RacerMate Inc., WA, USA), which will be digitally connected to a heart rate monitor and programmed to monitor the wattage of the bike based on the participant's heart rate. Exercise duration (15min-20min) and intensity (60%-75% max HR) will increase over the intervention period. For the remotely supervised sessions, exercise intensities and heart rate will be monitored via FitBit.
Study: NCT03206645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Unesbulin
Description: Unesbulin will be given in combination with carboplatin and paclitaxel for up to 7 cycles depending on which cohort the patient is in.
Study: NCT02169739

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ischemic Preconditioning
Description: Patients will undergo ischemic preconditioning once or twice daily for up to four 5-minutes cycles of bilateral upper extremity ischemia separated by 5-minute periods of reperfusion.